Abstract Xylooligosaccharide was found to have a favorable effect on human intestinal flora. Xylooligosaccharide was utilized by bifidobacteria, but it was not utilized by Escherichia coli and Clostridium spp. in vitro. In vivo, xylooligosaccharide (5 g/day) promoted the growth of bifidobacteria, lowered fecal pH and helped to maintain the fecal water content within normal range. These results showed that xylooligosaccharide can selectively promote the growth of bifidobacteria and help to establish favorable environmental conditions in the intestines.
An intestinal bacterial flora is closely related to human health conditions, and a predominance of Bifidobacterium is particularly considered to be beneficial (2, 3, 5, 8, 9, 12) .
Extensive studies have shown that various B(dobacterium-containing preparations and oligosaccharides used as energy sources by bifidobacteria are effective for stimulating the propagation of intestinal bifidobacteria (13, 16) , but there are problems with presently available products regarding their development in the intestine (14) , stability (Fuwa et al, 1982 ; presented at 1st Annual Meeting of Inst. of Neosugar, Tokyo) , and selective utilization by intestinal bacteria (6, 11, 17) . The purpose of this study was to solve these problems by using xylooligosaccharides. Here we describe the utilization of xylooligosaccharide by intestinal bacteria in vitro. And during oral administration of xylooligosaccharide at 5 g per day for 3 consecutive weeks, the effect on human intestinal flora, water content in feces and pH variation, which are considered to be related to the increase in bifidobacteria, are described.
MATERIALS AND METHODS
Preparation and composition of the test sugar (XO) . The xylooligosaccharide used was obtained from birch wood xylan hydrolyzed by Trichoderma-derived enzyme xylanase (Sumyzyme TX, Shin Nihon Chemical Co., Ltd.). It was decolored with active charcoal powder, desalted and concentrated. The methods for preparation Effect on Intestinal Bacterial Flora Table 2 shows the changes in intestinal microflora of the nine subjects who were administered xylooligosaccharide. There was no change in the total bacterial counts throughout the experimental period. The counts of Bifidobacterium increased significantly during administration of xylooligosaccharide (t-test, significant at 1 %), while those of Bacteroides and Clostridium did not increase during administration. In individual data (Fig. 1) , an increase in the counts of Bifidobacterium was recorded in 7 of 9 subjects. The remaining two subjects had very high counts of Bifidobacterium before administration. Figure 2 shows the relative percentage of each bacterial group to total bacteiral counts in the feces. Bifidobacterium increased to 24-32 %, compared with 12-17% before administration of xylooligosaccharide (t-test, significant at 1% level) . The percent of bifidobacteria significantly decreased after discontinuation of administration and there was no significant difference between the levels before and after administration. On the other hand, Bacteroides, which had accounted for 52 % at 2 weeks before administration, decreased to 26% at the 2nd week after administration had begun. In the individual data, all the subjects showed an increased relative percent of bifidobacteria during administration of xylooligosaccharide. The relative percent of Bacteroides dropped in 7 of the 9 subjects (Fig. 3) .
Changes in Fecal Water Content
The average fecal water content in the nine subjects, with the standard deviation of the mean, is shown in Fig. 4 . It varied between 66 and 90% before administration and tended to congregate at the 80% level during administration. The mean values were nearly 79%, while the standard deviation of approximately 10% pH Changes of Feces Figure 6 shows the mean fecal pH values of the nine subjects, which ranged from 6.16 to 6.29 before administration and from 5.95 to 6.08 during the period of xylooligosaccharide intake. Figure  7 shows presented at 12th Carbohydrate Symposium, Osaka) . Therefore, xylooligosaccharide can reach the lower digestive tract without being absorbed and can be utilized effectively as a growth-stimulating substance for bifidobacteria. In addition, xylobiose, a main component of xylooligosaccharide, is utilized by Bifidobacterium, especially by B. adolescentis, which is resident in most adults' intestines (10) . So this xylooligosaccharide might be suitable as a bifidus factor in adults. In fact, in the in vivo experiment, when the subjects ingested xylooligosaccharide, bifidobacteria counts increased from the 10% pre-administration level to 32 % at the 2nd week after the start of administration. As the relative percentage of bifidobacteria decreased after discontinuation of the administration, we concluded that the increase had been due to the effect of xylooligosaccharide. As administration of xylooligosaccharide selectively increased bifidobacteria and hardly caused any increase in other bacteria, xylooligosaccharide was found to be an effective bifidus factor. Fecal pH decreased during administration of xylooligosaccharide. In this study, significant difference in the amount of fecal ammonia was not observed (data not shown), but increased fecal acetic acid was observed during administration. These results suggest that this lowered pH might be caused mainly by the increased amount of acetic acid. As a low pH stimulates the intestinal lining and promotes intestinal peristalsis, improvement of constipation might be expected (15, 18) . Also, evidence that ingested xylooligosaccharide tends to maintain fecal water content within normal level indicates that both hard and soft feces attain a suitable fecal firmness.
VFA Changes in Feces
In summary, xylooligosaccharide increased the amount of intestinal bifidobacteria, lowered the fecal pH and maintained the fecal water content within normal range, which all contributed to the establishment of suitable environmental conditions for the intestine. These effects of xylooligosaccharide could be attained with a daily dose of 2 g.
